Anti-human TROP-2 antibody having anti-tumor activity in vivo
AssigneeLivtech, Inc.
InventorsKoji Nakamura, Kentaro Okamura, Maki Tamura, Hiroyuki Yanai, Toru Kanke
Life of this patent
Estimating the term…
Abstract
The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.
Claims45
An antibody against human TROP-2, which has anti-tumor activity in vivo, wherein the amino acid sequences of CDR 1 to 3 of the H chain V region of the antibody are shown in SEQ ID NOS:
- 66 to 68, respectively, and/or the amino acid sequences of CDR 1 to 3 of the L chain V region of the antibody are shown in SEQ ID NOS:
- 71 to 73, respectively.
An antigen binding fragment derived from an antibody against human TROP-2, which has anti-tumor activity in vivo, wherein the fragment comprises the amino acid sequences shown in SEQ ID NOS:
- 66 to 68 and/or the amino acid sequences shown in SEQ ID NOS:
- 71 to 73.
A recombinant antibody against human TROP-2, which is a chimeric antibody, a humanized antibody, or a human antibody, and has anti-tumor activity in vivo, wherein the H chain V region of the chimeric antibody consists of the amino acid sequence shown in SEQ ID NO:
- 65, and/or the L chain V region thereof consists of the amino acid sequence shown in SEQ ID NO:
- 70.
A monoclonal antibody against human TROP-2, which is produced by a hybridoma having accession No. FERM BP-11346.
A hybridoma producing a monoclonal antibody against human TROP-2, which has accession No. FERM BP-11346.
An antibody against human TROP-2, which has anti-tumor activity in vivo, which binds to the same epitope, to which the monoclonal antibody produced by the hybridoma having accession No. FERM BP-11346 binds.
Dependencies are inferred from the claim text.